ATP-vezujuća kaseta, potfamilija B (MDR/TAP), član 1
Kristalografska struktura MDR3 proteina miša. Približna pozicija proteina u ćelijskoj membrani je obeležena plavim (ekstracelularno lice) i crvenim (citoplazmatično lice) linijama. Protein je prikaza u bojama duge (N-terminus = plavo, C-terminus = crveno). Ciklični peptidni inhibitor QZ59 je prikazan kao prostorno popunjavajući model.[1]
P-glikoprotein 1 (glikoprotein permeabilnosti, P-gp, Pgp, protein otpornosti na višestruke lekove 1, MDR1, ATP-vezujuća kaseta potfamilija B član 1, ABCB1, klaster of diferencijacije 243, CD243) je glikoprotein koji je kod ljudi kodiran ABCB1genom.[2] P-gp dobro poznati ABC-transporter (koji transportuje široki opseg supstrata kroz ekstra- i intracelularne membrane). On je član MDR/TAP familije.[3]
Ling V (1997). „Multidrug resistance: molecular mechanisms and clinical relevance”. Cancer Chemother. Pharmacol. 40 Suppl (7): S3—8. PMID9272126. doi:10.1007/s002800051053.
Kerb R, Hoffmeyer S, Brinkmann U (2001). „ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2”. Pharmacogenomics. 2 (1): 51—64. PMID11258197. doi:10.1517/14622416.2.1.51.
Akiyama S (2002). „[Mechanisms of drug resistance and reversal of the resistance]”. Hum. Cell. 14 (4): 257—60. PMID11925925.
Brinkmann U (2002). „Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo”. Novartis Found. Symp. Novartis Foundation Symposia. 243: 207—10; discussion 210—2, 231—5. ISBN978-0-470-84635-3. PMID11990778. doi:10.1002/0470846356.ch15.
Váradi A, Szakács G, Bakos E, Sarkadi B (2002). „P glycoprotein and the mechanism of multidrug resistance”. Novartis Found. Symp. Novartis Foundation Symposia. 243: 54—65; discussion 65—8, 180—5. ISBN978-0-470-84635-3. PMID11990782. doi:10.1002/0470846356.ch5.
Hegedus T; Orfi L; Seprodi A; et al. (2002). „Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1”. Biochim. Biophys. Acta. 1587 (2–3): 318—25. PMID12084474.CS1 одржавање: Експлицитна употреба et al. (веза)
Pallis M, Turzanski J, Higashi Y, Russell N (2003). „P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype”. Leuk. Lymphoma. 43 (6): 1221—8. PMID12152989. doi:10.1080/10428190290026277.
Schaich M, Illmer T (2003). „Mdr1 gene expression and mutations in Ras proto-oncogenes in acute myeloid leukemia”. Leuk. Lymphoma. 43 (7): 1345—54. PMID12389613. doi:10.1080/10428190290033279.
Fromm MF (2003). „The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans”. Adv. Drug Deliv. Rev. 54 (10): 1295—310. PMID12406646. doi:10.1016/S0169-409X(02)00064-9.
Ambudkar SV; Kimchi-Sarfaty C; Sauna ZE; Michael M. Gottesman (2003). „P-glycoprotein: from genomics to mechanism”. Oncogene. 22 (47): 7468—85. PMID14576852. doi:10.1038/sj.onc.1206948.
Jamroziak K, Robak T (2004). „Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies”. Hematology. 9 (2): 91—105. PMID15203864. doi:10.1080/10245330310001638974.
Ishikawa T; Onishi Y; Hirano H; et al. (2005). „Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1)”. Biol. Pharm. Bull. 27 (7): 939—48. PMID15256718. doi:10.1248/bpb.27.939.CS1 одржавање: Експлицитна употреба et al. (веза)
Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005). „Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development”. Oncologist. 10 (2): 104—11. PMID15709212. doi:10.1634/theoncologist.10-2-104.
Gambrelle J; Labialle S; Dayan G; et al. (2005). „[Multidrug resistance in uveal melanoma.]”. Journal français d'ophtalmologie. 28 (6): 652—9. PMID16141933.CS1 одржавање: Експлицитна употреба et al. (веза)
Annese V; Valvano MR; Palmieri O; et al. (2006). „Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis”. World J. Gastroenterol. 12 (23): 3636—44. PMID16773678.CS1 одржавање: Експлицитна употреба et al. (веза)
Sekine I; Minna JD; Nishio K; et al. (2007). „A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer”. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 1 (1): 31—7. PMID17409824.CS1 одржавање: Експлицитна употреба et al. (веза)
Kumar YS, Adukondalu D, Sathish D, Vishnu YV, Ramesh G, Latha AB, Reddy PC, Sarangapani M, Rao YM (2010). „P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions”. Drug Metabol Drug Interact. 25 (1-4): 3—16. PMID21417789. doi:10.1515/DMDI.2010.006.
Spoljašnje veze
P-Glycoprotein на US National Library of Medicine Medical Subject Headings (MeSH)
Jessica R Oesterheld (1. 5. 2002). „P-glycoprotein”. Mental Health Connections, Inc. Архивирано из оригинала 7. 2. 2008. г. Приступљено 2. 3. 2008.